World Health Organization, Media Centre. Depression Fact Sheet. Updated September 13 2021. https://www.who.int/news-room/fact-sheets/detail/depression. Accessed November 2022.

Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17.

Article  PubMed  Google Scholar 

Bobo WV, Vande Voort JL, Croarkin PE, Leung JG, Tye SJ, Frye MA. Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice. Depress Anxiety. 2016;33:698–710.

Article  PubMed  CAS  Google Scholar 

Kryst J, Kawalec P, Mitoraj AM, Pilc A, Lasón W, Brzostek T. Efficacy of a single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharm Rep. 2020;72:543–62.

Article  CAS  Google Scholar 

Nikolin S, Rodgers A, Schwaab A, Bahji A, Zarate C Jr, Vazquez G, et al. Ketamine for the treatment of major depression: a systematic review and meta-analysis. EClinicalMedicine. 2023;62:102127.

Article  PubMed  PubMed Central  Google Scholar 

Papakostas GI. Maintaining rapid antidepressant effects following ketamine infusion: a major unmet need. J Clin Psychiatry. 2020;81:19r12859.

Article  PubMed  Google Scholar 

Smith-Apeldoorn SY, Veraart JKE, Spijker J, Kamphuis J, Schoevers RA. Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. Lancet Psychiatry. 2022;9:907–21.

Article  PubMed  Google Scholar 

Zheng W, Cai D, Xiang Y, Zheng W, Jiang W, Sim K, et al. Adjunctive intranasal esketamine for major depressive disorder: a systematic review of randomized double-blind controlled-placebo studies. J Affect Disord. 2020;265:63–70.

Article  PubMed  CAS  Google Scholar 

Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176:428–38.

Article  PubMed  Google Scholar 

Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76:893–903.

Article  PubMed  PubMed Central  Google Scholar 

Ross EL, Soeteman DI. Cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the United States. Psychiatr Serv. 2020;71:988–97.

Article  PubMed  PubMed Central  Google Scholar 

Loo C, Glozier N, Barton D, Baune BT, Mills NT, Fitzgerald P, et al. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial. Br J Psychiatry. 2023;223:1–9.

Article  Google Scholar 

Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H. Answering patients’ needs: oral alternatives to intravenous therapy. Oncologist. 2001;6:12–6.

Article  PubMed  Google Scholar 

Schoevers RA, Chaves TV, Balukova SM, Aan het Rot M, Kortekaas R. Oral ketamine for the treatment of pain and treatment-resistant depression. Br J Psychiatry. 2016;208:108–13.

Article  PubMed  Google Scholar 

Rosenblat JD, Carvalho AF, Li M, Lee Y, Subramanieapillai M, McIntyre RS. Oral ketamine for depression: a systematic review. J Clin Psychiatry. 2019;80:18r12475.

Article  PubMed  Google Scholar 

Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, Van Asselt ADI, Touw DJ, Aan Het Rot M, et al. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial. BMC Psychiatry. 2019;19:375.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22–33.

PubMed  Google Scholar 

Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278–96.

Article  PubMed  CAS  Google Scholar 

Netherlands National Health Care Institute. August 27 2021. https://www.nvvp.net/nieuws/2021/esketamine-neusspray-in-verzekerd-pakket. Accessed November 2023.

Smith-Apeldoorn SY, Veraart JKE, Ruhé HG, Aan het Rot M, Kamphuis J, De Boer MK, et al. Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study. BJPsych Open. 2021;8:e4.

Article  PubMed  PubMed Central  Google Scholar 

Andrade C. Oral ketamine for depression, 1: pharmacologic considerations and clinical evidence. J Clin Psychiatry. 2019;80:19f12820.

PubMed  Google Scholar 

Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The inventory of depressive symptomatology (IDS). Psychol Med. 1986;26:477–86.

Article  Google Scholar 

Guy W ECDEU Assessment Manual for Psychopharmacology. Rockville, MD, US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, 1976.

Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Versteegh MM, Vermeulen KM, Evers SMAA, De Wit GA, Prenger R, Stolk EA. Dutch tariff for the five-level version of EQ-5D. Value Health. 2016;19:343–52.

Article  Google Scholar 

Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22:343–81.

PubMed  CAS  Google Scholar 

Aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67:139–45.

Article  PubMed  CAS  Google Scholar 

Stiglmayr C, Schimke P, Wagner T, Braakmann D, Schweiger U, Sipos V, et al. Development and psychometric characteristics of the Dissociation Tension Scale. J Pers Assess. 2010;92:269–77.

Article  PubMed  Google Scholar 

Rossell SL, Schutte MJL, Toh WL, Thomas N, Strauss C, Linszen MMJ, et al. The Questionnaire for psychotic experiences: an examination of the validity and reliability. Schizophr Bull. 2019;45:S78–87.

Article  PubMed  PubMed Central  Google Scholar 

Koffel E, Watson D. Development and initial validation of the Iowa Sleep Disturbances Inventory. Assessment. 2010;17:423–39.

Article  PubMed  PubMed Central  Google Scholar 

Twisk J, Bosman L, Hoekstra T, Rijnhart J, Welten M, Heymans M. Different ways to estimate treatment effects in randomized controlled trials. Contemp Clin Trials Commun. 2018;10:80–5.

Article  Google Scholar 

Lara DR, Bisol LW, Munari LR. Antidepressant, mood stabilizing and precognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neurophsychopharmacol. 2013;16:2111–7.

Article  CAS  Google Scholar 

Glue P, Medlicott NJ, Neehoff S, Surman P, Lam F, Hung N, et al. Safety and efficacy of extended-release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study. Ther Adv Psychopharmacol. 2020;10:2045125320922474.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Arabzadeh S, Hakkikazazi E, Shahmansouri N, Tafakhori A, Ghajar A, Jafarinia M, et al. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial. J Affect Disord. 2018;235:236–41.

Article  PubMed  CAS  Google Scholar 

Levinta A, Meshkat S, McIntyre RS, Ho C, Lui LMW, Lee Y, et al. The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: a systematic review. J Affect Disord. 2022;318:139–49.

Article  PubMed  CAS  Google Scholar 

Loo CK, Gálvez V, O’Keefe E, Mitchell PB, Hadzi-Pavlovic D, Leyden J, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand. 2016;134:48–56.

Article  PubMed  CAS  Google Scholar 

Jelen LA, Young AH, Stone JM. Ketamine: a tale of two enantiomers. J Psychopharmacol. 2021;35:109–23.

Article  PubMed  CAS  Google Scholar 

Smith-Apeldoorn SY, Vischjager M, Veraart JKE, Kamphuis J, Aan het Rot M, Schoevers RA. The antidepressant effect and safety of non-intranasal esketamine: a systematic review. J Psychopharmacol. 2022;36:531–44.

Article  PubMed  PubMed Central  Google Scholar 

Correia-Melo FS, Leal GC, Vieira F, Jesus-Nunes AP, Mello RP, Magnavita G, et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord. 2020;264:527–34.

Article  PubMed  CAS  Google Scholar 

Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;278:542–55.

Article  PubMed  CAS  Google Scholar